AbbVie Inc. (ABBV)

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Ticker
ABBV
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - General
Market cap
$521.06B
52-week range
$190.75 - $302.93

Valuation

Share price
$294.55 (close of Nov 16, 2026)
P/E (TTM)
50.52x
Price to book
-114.82x
Price to free cash flow
27.61x
Enterprise value
$591.19B
Book value per share
$-2.57

Price performance

PeriodChange
1 day-0.16%
5 days+0.43%
1 month+3.20%
3 months+18.08%
6 months+40.00%
Year to date+28.91%
1 year+26.76%
3 years+113.01%
5 years+153.01%
10 years+378.63%
All time+738.70%

Short interest

As of
Oct 30, 2026
Short % of float
0.99%
Shares short
15.81M
Days to cover
3.32
Change since prior report
+1.48%
Source
FINRA consolidated short interest

Members of Congress who disclosed ABBV trades

Lisa McClain · Josh Gottheimer · Julia Letlow · Jared Moskowitz · Julie Johnson · Marjorie Taylor Greene · Robert Bresnahan · Jefferson Shreve · John Boozman · Ritchie Torres · Alan Armstrong · Dwight Evans

And 2 others

Super investors holding ABBV

Ken Griffin (Citadel) · Mairs & Power (Mairs & Power Inc) · David Katz (Matrix Asset Advisors Inc) · Thomas Russo (Gardner Russo & Quinn LLC) · Ray Dalio (Bridgewater Associates) · Dodge & Cox (Dodge & Cox Funds) · Bill Nygren (Harris Associates LP)

Profitability and growth

Return on invested capital
19.78%
Return on assets
3.15%
Return on capital employed
16.63%
Gross margin
70.24%
Net margin
6.91%
EBITDA margin
37.96%
Revenue growth
8.57%
Net income growth
-1.22%
Free cash flow growth
-0.09%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.62%
Current ratio
0.87x
Net debt to EBITDA
2.99x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$61.16B
Cost of revenue
$18.20B
Gross profit
$42.96B
EBITDA
$23.21B
Net income
$4.23B
Earnings per share
$2.37
Research and development
$9.10B
Interest expense
$2.89B
Shares outstanding
1.77B

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$61.16B$42.96B$4.23B$2.37
2024-12-31$56.33B$39.43B$4.28B$2.40
2023-12-31$54.32B$33.90B$4.86B$2.73
2022-12-31$58.05B$40.64B$11.84B$6.65
2021-12-31$56.20B$38.75B$11.54B$6.48
2020-12-31$45.80B$30.42B$4.62B$2.73
2019-12-31$33.27B$25.83B$7.88B$5.30
2018-12-31$32.75B$25.04B$5.69B$3.67
2017-12-31$28.22B$21.17B$5.31B$3.31
2016-12-31$25.64B$19.81B$5.95B$3.65

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3170.24%6.91%-19.78%
2024-12-3169.99%7.59%-12.96%
2023-12-3162.42%8.95%46.77%16.31%
2022-12-3170.00%20.39%68.47%20.46%
2021-12-3168.96%20.54%74.77%17.85%
2020-12-3166.41%10.08%35.24%11.46%
2019-12-3177.64%23.69%-19.69%
2018-12-3176.44%17.36%-21.10%
2017-12-3175.04%18.82%104.16%19.55%
2016-12-3177.25%23.22%128.41%17.87%

Cash and debt by year

Period endCashDebt
2025-12-31$5.26B$64.50B
2024-12-31$5.55B$66.84B
2023-12-31$12.82B$59.24B
2022-12-31$9.23B$63.13B
2021-12-31$9.83B$75.96B
2020-12-31$8.48B$84.95B
2019-12-31$39.92B$67.23B
2018-12-31$8.06B$35.00B
2017-12-31$9.79B$30.95B
2016-12-31$6.42B$36.44B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$17.82B$955.00M
2024-12-31$17.83B$911.00M
2023-12-31$22.06B$747.00M
2022-12-31$24.25B$671.00M
2021-12-31$21.99B$692.00M
2020-12-31$16.79B$753.00M
2019-12-31$12.77B$430.00M
2018-12-31$12.79B$421.00M
2017-12-31$9.43B$365.00M
2016-12-31$6.56B$353.00M

Dividend history

Most recent payment
Oct 15, 2026
Paid in the last twelve months
$6.92
Payment dateDividend per share
2026-10-15$1.73
2026-07-15$1.73
2026-04-15$1.73
2026-01-16$1.73
2025-10-15$1.64
2025-07-15$1.64
2025-04-15$1.64
2025-01-15$1.64

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-10-30Sep 2026$3.74
2026-07-31Jun 2026$3.64
2026-04-29Mar 2026$2.62
2026-02-04Dec 2025$2.66
2025-10-31Sep 2025$1.77
2025-07-31Jun 2025$2.89
2025-04-25Mar 2025$2.39
2025-01-31Dec 2024$2.13

Filings and sources

Company website
abbvie.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Merck & Co., Inc. (MRK) · Johnson & Johnson (JNJ) · Novartis AG (NVS) · Eli Lilly & Co (LLY) · AstraZeneca plc (AZN) · Amgen Inc (AMGN) · Gilead Sciences, Inc. (GILD) · Pfizer Inc (PFE)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades